exclud
infect
acquir
parenter
virtual
infect
acquir
via
mucos
surfac
gastrointestin
genit
tract
heterosexu
transmiss
genit
tract
mucosa
site
viral
entri
wherea
vertic
transmiss
infect
result
oralgenit
analgenit
contact
gastrointestin
tract
mucosa
portal
entri
vertic
transmiss
upper
gastrointestin
tract
mucosa
site
viral
entri
consequ
swallow
infect
amniot
fluid
utero
infect
blood
cervic
secret
intrapartum
infect
breast
milk
postpartum
homosexu
transmiss
oralgenit
contact
recent
shown
common
analgenit
contact
suggest
upper
gastrointestin
tract
mucosa
common
site
entri
rectal
mucosa
inde
quarter
primari
infect
one
seri
unit
state
result
exclus
recept
oralgenit
exposur
infecti
new
inform
infecti
person
carri
viru
base
larg
studi
heterosexu
transmiss
nevertheless
mani
factor
promot
transmiss
across
vagin
mucosa
probabl
also
enhanc
transmiss
across
gastrointestin
mucosa
tabl
exampl
infecti
defin
probabl
transmit
one
person
anoth
greatest
index
partner
primari
infect
correspond
period
infect
exposur
viru
develop
circul
antibodi
primari
infect
associ
highest
plasma
level
although
level
genit
secret
primari
infect
report
viru
detect
genit
secret
stage
diseas
thu
presenc
cellfre
cellassoci
viru
genit
secret
probabl
contribut
increas
infecti
stage
diseas
latestag
diseas
also
associ
increas
level
blood
semen
mani
infect
men
associ
increas
risk
transmiss
presenc
reproduct
tract
inflamm
infect
urethr
gonorrhea
cytomegaloviru
infect
also
increas
infecti
donor
like
increas
shed
semen
genotyp
differ
viru
isol
semen
blood
subject
argu
local
product
viru
genit
tract
infect
men
summari
viral
load
blood
key
predictor
risk
heterosexu
transmiss
blood
viral
load
gener
correl
genit
secret
thu
amount
viru
inocul
onto
mucos
surfac
includ
gastrointestin
mucosa
import
factor
transmiss
suscept
recipi
partner
also
import
factor
assess
probabl
transmiss
across
gastrointestin
tract
mucosa
normal
intact
mucosa
prevent
mucos
penetr
mani
lumin
pathogen
person
risk
infect
traumainduc
disrupt
rectal
mucosa
provid
inocul
viru
direct
access
mucos
microcircul
contribut
high
rate
transmiss
recept
anal
intercours
similarli
infectionassoci
mucos
inflamm
eros
probabl
provid
viru
access
lymphoid
cell
lamina
propria
support
latter
notion
clinic
observ
certain
gastrointestin
tract
infect
caus
mucos
ulcer
deep
eros
includ
herp
simplex
proctiti
syphili
associ
higher
rate
transmiss
addit
certain
mucos
infect
enhanc
suscept
lymphoid
cell
infect
exampl
mycobacterium
avium
complex
mac
enhanc
macrophag
express
chemokin
coreceptor
macrophagetrop
upregul
express
macrophag
coinfect
mac
genet
also
play
role
suscept
infect
certain
popul
approxim
white
individu
delet
allel
gene
encod
chemokin
receptor
serv
coreceptor
macrophagetrop
entri
mononuclear
cell
homozyg
express
defect
allel
lead
absenc
function
coreceptor
consequ
mononuclear
cell
resist
infect
macrophagetrop
predomin
transmit
strain
macrophagetrop
person
homozyg
allel
suscept
infect
isol
final
spectrum
behavior
sociolog
factor
includ
increas
frequenc
sexual
contact
unprotect
sexual
contact
recept
anal
intercours
absenc
circumcis
men
associ
increas
transmiss
among
person
gastrointestin
tract
rout
entri
absenc
mucos
disrupt
trauma
infect
propos
rout
entri
mononuclear
cellrich
lamina
propria
includ
cell
dendrit
cell
epitheli
cell
figur
cell
special
epitheli
cell
present
dome
overli
peyer
patch
small
intestin
lymphoid
follicl
rectum
cell
transport
macromolecul
microorgan
includ
virus
polioviru
reoviru
nondegrad
pathway
interdigit
mononuclear
cell
possibl
dendrit
cell
underli
lymphoid
structur
ex
vivo
system
mous
rabbit
cell
capabl
transport
mononuclear
cell
simian
immunodefici
viru
siv
model
atraumat
inocul
siv
oral
caviti
lead
rapid
infect
tonsil
rich
sourc
cell
suggest
cell
uptak
transport
viru
howev
human
cell
yet
report
take
transport
probabl
reflect
rapid
transport
process
unavail
tissu
specimen
subject
shortli
viru
inocul
nevertheless
high
preval
cell
rectum
tonsil
strateg
posit
cell
potenti
role
transport
vertic
analgenit
transmiss
dendrit
cell
highli
effici
antigenpres
cell
express
dendrit
cell
assum
characterist
stellat
morpholog
tissu
identifi
rat
small
larg
intestin
mous
peyer
patch
macaqu
cervicovagin
mucosa
foreskin
human
tonsil
adenoid
tonsilar
dendrit
cell
form
conjug
cell
result
high
level
viral
replic
cell
vitro
recent
evid
indic
dendrit
cell
bind
envelop
ctype
lectin
allow
captur
infect
subsequ
deliveri
cell
dissemin
secondari
lymphoid
organ
whether
dendrit
cell
involv
pathogenesi
infect
human
small
intestin
unclear
unabl
identifi
dendrit
cell
human
small
intestin
lamina
propria
studi
lamina
propria
mononuclear
cell
isol
normal
jejunum
express
dendrit
cell
marker
includ
display
ultrastructur
characterist
dendrit
cell
addit
treatment
purifi
lamina
propria
macrophag
optim
concentr
glomerulocytemacrophag
colonystimul
factor
tumor
necrosi
factor
interleukin
induc
dendrit
cell
howev
cell
thought
dendrit
cell
identifi
morpholog
colon
lamina
propria
mononuclear
cell
newli
avail
dendrit
cellspecif
antibodi
facilit
confirm
observ
whether
dendrit
cell
colon
particip
entri
pathogenesi
await
studi
epitheli
cell
abund
cell
type
line
mucosa
intestin
colon
potenti
import
conduit
entri
recent
studi
mucos
transloc
use
epitheli
cell
line
show
viru
could
transloc
across
tight
epitheli
cell
monolay
transcytot
pathway
howev
phenotyp
epitheli
tumor
cell
line
differ
primari
intestin
epitheli
cell
therefor
use
modif
techniqu
develop
isol
purifi
human
intestin
macrophag
lymphocyt
purifi
human
intestin
epitheli
cell
studi
receptor
coreceptor
express
primari
intestin
epitheli
cell
express
galactosyl
ceramid
galcer
altern
primari
receptor
neural
epitheli
line
addit
primari
intestin
epitheli
cell
express
coreceptor
macrophagetrop
isol
refer
virus
use
cell
entri
contrast
express
primari
intestin
epitheli
cell
express
chemokin
coreceptor
lymphocytetrop
isol
refer
virus
use
entri
primari
receptor
mononuclear
cell
galcer
phenotyp
distinguish
primari
intestin
epitheli
cell
epitheli
cell
line
indic
cell
equip
select
uptak
present
upper
gastrointestin
tract
mucosa
phenotyp
purifi
rectal
epitheli
cell
yet
report
although
immunohistochem
stain
colon
biopsi
specimen
suggest
may
present
rectal
epithelium
indic
intestin
epithelium
may
differ
colon
epithelium
coreceptor
express
isol
acut
infect
person
predominantli
time
mutat
lead
emerg
virus
result
presenc
mixtur
virus
chronic
infect
person
infect
acquir
across
mucos
surfac
mucos
cell
could
conceiv
select
virus
initi
acquir
recipi
mixtur
virus
inocul
onto
mucosa
chronic
infect
donor
shown
intestin
epitheli
cell
express
investig
whether
cell
could
select
transfer
target
cell
found
intestin
epitheli
cell
select
transfer
target
cell
replic
amplifi
viru
express
addit
studi
support
bomsel
observ
cell
line
transfer
accomplish
microtubuledepend
transcytosi
find
intestin
epitheli
cell
select
transfer
exclus
virus
offer
mechan
select
transmiss
primari
infect
acquir
upper
gastrointestin
tract
figur
cross
epithelium
enter
lamina
propria
viru
encount
largest
reservoir
macrophag
lymphocyt
bodi
studi
biolog
paramet
infect
cell
show
lamina
propria
macrophag
surprisingli
express
permiss
vitro
observ
may
explain
low
preval
macrophag
upper
gastrointestin
tract
mucosa
vivo
indic
intestin
macrophag
probabl
particip
select
virus
primari
infect
intestin
lymphocyt
hand
express
support
replic
vitro
indic
intestin
lymphocyt
also
probabl
particip
select
acquisit
virus
primari
infect
figur
thu
epitheli
cell
rather
resid
macrophag
lymphocyt
appear
mucos
cell
capabl
select
primari
infect
seri
insight
vivo
studi
infect
human
siv
infect
rhesu
macaqu
sought
dissect
earli
event
mucos
infect
consist
find
human
intestin
lymphocyt
macrophag
target
cell
infect
vitro
veazey
et
al
show
first
day
siv
infect
macaqu
infect
macrophag
rare
virusinfect
cell
present
intestin
mucosa
blood
viru
replic
effici
activ
cell
greater
abund
activ
cell
lamina
propria
blood
probabl
account
initi
higher
frequenc
virusinfect
lymphocyt
gastrointestin
mucosa
blood
coincid
earli
local
accumul
sivinfect
lymphocyt
presenc
high
viral
load
intestin
mucosa
importantli
earli
high
viral
load
intestin
mucosa
sivinfect
macaqu
associ
villou
atrophi
malabsorpt
consist
sivinduc
enteropathi
howev
day
infect
cell
intestin
colon
mucosa
becam
rapidli
profoundli
deplet
probabl
consequ
cell
lysi
apoptosi
profound
deplet
mucos
cell
occur
predominantli
lamina
propria
prece
deplet
cell
blood
human
macaqu
taken
togeth
studi
discuss
suggest
follow
sequenc
event
intestin
mucosa
earli
infect
acquir
vertic
transmiss
homosexu
contact
mixtur
virus
typic
present
blood
chronic
infect
donor
releas
milk
semen
enter
recipi
inocul
oral
caviti
oral
caviti
viru
reach
tonsil
encount
cell
overli
epithelium
cell
deliv
viru
dendrit
cellrich
lymphoid
tissu
tonsil
although
dendrit
cell
alon
support
replic
dendrit
cellt
cell
conjug
support
high
level
viral
replic
dendrit
cell
normal
migrat
lymphat
secondari
lymphoid
organ
contain
ctype
lectin
trap
viru
thu
may
particip
dissemin
gastrointestin
tract
lymphoid
tissu
oral
caviti
viru
mix
saliva
contain
antivir
factor
includ
secretori
leukocyt
proteas
potent
inhibitor
activ
factor
may
prevent
local
tonsilar
infect
allow
swallow
viru
pass
oral
caviti
passag
stomach
would
facilit
absenc
gastric
acid
product
fetu
neonat
adult
gastric
acid
could
limit
amount
viabl
viru
reach
intestin
issu
requir
studi
thu
mixtur
inocul
virus
reach
recipi
upper
gastrointestin
tract
mucosa
galcer
epitheli
cell
bind
select
transfer
virus
cell
apic
basolater
surfac
probabl
microtubuledepend
nondegrad
transcytosi
viru
transloc
across
epithelium
encount
lamina
propria
macrophag
cell
lymphocyt
express
coreceptor
mediat
entri
lamina
propria
contain
largest
reservoir
activ
cell
bodi
replic
effici
activ
cell
lamina
propria
becom
initi
major
site
replic
amplif
viru
infect
activ
cell
organ
lymphoid
structur
possibl
via
cell
uptak
transport
could
dissemin
distant
mucos
site
normal
receptormedi
home
soon
cell
death
cell
lysi
apoptosi
cytotox
lymphocyteinduc
kill
lead
rapid
deplet
lamina
propria
cell
long
decreas
circul
cell
eventu
local
immunosuppress
induc
cell
deplet
predispos
gastrointestin
tract
mucosa
array
opportunist
infect
lead
mucos
inflamm
releas
chemoattract
peptid
peptid
recruit
mucosa
monocyt
lymphocyt
serv
new
target
cell
perpetu
local
replic
consequ
inflamm
possibl
local
hiv
infect
mucos
function
compromis
malabsorpt
ensu
even
opportunist
infect
induc
clinic
symptom
thu
besid
serv
site
opportunist
infect
latestag
diseas
gastrointestin
tract
also
play
fundament
role
earli
diseas
serv
site
viru
entri
initi
site
viru
replic
amplif
initi
site
cell
deplet
veazey
et
al
aptli
suggest
gastrointestin
tract
mucosa
peripher
lymphoid
tissu
initi
tissu
site
diseas
initi
event
consequ
extens
infect
intestin
cell
patient
show
rapid
dramat
persist
decreas
number
cell
lamina
propria
preced
peripher
site
immunolog
insult
mucosa
associ
rang
physiolog
morpholog
perturb
lead
remark
increas
rate
oral
esophag
gastrointestin
symptom
rate
secondari
opportunist
infect
correl
number
peripher
cell
presum
mucosa
promin
among
syndrom
chronic
diarrhea
chronic
diarrhea
affect
adult
resourcepoor
nation
rel
recent
unit
state
western
europ
number
excel
primari
investig
review
reveal
sequenti
comprehens
approach
specif
organ
identifi
patient
diarrhea
infect
effect
treat
suppress
tabl
diagnost
algorithm
specif
therapi
conveni
outlin
howev
perhap
effect
approach
prevent
treatment
mucos
infect
mani
opportunist
infect
among
patient
diseas
recent
introduct
haart
haart
result
therapi
first
antiretrovir
agent
avail
zidovudin
zdv
azt
show
first
time
chemotherapi
could
retard
progress
diseas
lower
incid
opportunist
infect
death
subsequ
analys
result
indic
durat
singleag
antivir
activ
limit
develop
resist
inadequ
control
viral
replic
thu
similar
success
control
tuberculosi
multipl
antiretrovir
agent
develop
suppress
replic
long
period
decreas
diseas
progress
prevent
revers
immunolog
incompet
power
cocktail
agent
improv
natur
histori
infect
combin
inhibitor
revers
transcriptas
proteas
provid
haart
reversetranscriptas
inhibitor
rti
nucleosid
analogu
nrti
zdv
nonnucleosid
analogu
nnrti
primarili
inhibit
abil
rna
encod
viral
dna
integr
host
genom
attach
cell
membran
releas
envelop
entri
cytoplasm
retrovir
rna
gener
doublestrand
dna
proviru
revers
transcriptas
provir
dna
enter
nucleu
integr
host
cell
genom
dna
viral
replic
initi
particularli
activ
cell
howev
prolong
rti
therapi
sitespecif
mutat
pol
gene
encod
revers
transcriptas
confer
progress
resist
rti
therapi
necessit
use
addit
agent
limit
viral
replic
develop
resist
proteas
inhibitor
pi
second
major
class
antiretrovir
agent
induc
dosedepend
inhibit
aspart
proteas
requir
product
matur
infecti
virion
block
cleavag
gagpol
polyprotein
precursor
requisit
structur
core
protein
enzym
revers
transcriptas
integras
proteas
pi
caus
product
abnorm
viral
protein
noninfecti
virion
howev
develop
select
mutat
proteas
therapi
lead
resist
resist
one
pi
affect
suscept
pi
thu
virtual
current
haart
regimen
includ
agent
typic
pi
nrti
diminish
ablat
viral
replic
reflect
reduct
viral
load
prevent
develop
resist
enhanc
recoveri
immunolog
compet
result
increas
cell
number
improv
clinic
statu
base
cdc
stage
clinic
goal
therapi
prevent
ill
prolong
surviv
haart
dramat
reduc
death
rate
among
patient
infect
period
widespread
use
present
among
us
patient
advanc
diseas
cell
count
cellsl
normal
cellsl
mortal
decreas
per
personyear
concomitantli
incid
three
common
opportunist
infect
pneumocysti
carinii
pneumonia
mac
diseas
cytomegaloviru
cmv
retin
decreas
figur
b
decreas
proport
intens
antiretrovir
therapi
promin
among
person
combin
picontain
regimen
similar
result
report
western
europ
aidsdefin
ill
figur
infect
unit
state
decreas
rate
signific
number
complic
involv
alimentari
tract
includ
esophag
candidiasi
mac
cmv
cryptosporidiosi
herp
simplex
viru
well
kaposi
sarcoma
nonhodgkin
lymphoma
thu
combin
antiretrovir
therapi
particularli
haart
signific
impact
natur
histori
infect
substanti
reduc
incid
infecti
neoplast
diseas
includ
gastrointestin
tract
well
death
dramat
effect
haart
mortal
infect
like
caus
inhibit
replic
consequ
recoveri
immun
function
antiretrovir
agent
littl
activ
virus
pathogen
decreas
mortal
rate
infect
introduct
pi
haart
associ
earlier
recognit
infect
treatment
zdv
rapid
diagnosi
treatment
specif
opportunist
infect
prophylact
therapi
trimethoprimsulfamethoxazol
tmpsmx
pneumocysti
carinii
pneumonia
toxoplasmosi
widespread
introduct
zdv
tmpsmx
activ
gramneg
bacteria
also
associ
dramat
decreas
nontyphi
salmonella
infect
unit
state
time
salmonella
speci
common
caus
enter
bacteremia
patient
remain
african
patient
diseas
today
activ
pi
aprenavir
giardia
lamblia
adefovir
dipivoxil
dna
virus
herp
simplex
viru
cmv
hepat
b
viru
antiretrovir
agent
shown
littl
activ
viral
bacteri
protozoan
fungal
pathogen
thu
recoveri
immun
function
probabl
underli
much
clinic
benefit
accompani
viral
suppress
antiretrovir
therapi
substanti
immunolog
benefit
result
reduct
level
blood
lymphoid
tissu
follow
haart
benefit
includ
increas
number
cell
decreas
b
cell
activ
subsequ
enhanc
specif
prolif
respons
restor
function
architectur
lymph
node
howev
function
immunolog
recoveri
occur
mani
month
consequ
rate
infect
decreas
promin
month
potent
antiretrovir
therapi
thu
data
support
recommend
discontinu
prophylact
therapi
opportunist
infect
initi
haart
confirm
safeti
recommend
patient
whose
cell
level
increas
cellsl
total
lymphocyt
week
haart
potenti
effect
natur
histori
infect
includ
enter
infect
first
effect
control
result
decreas
incid
secondari
infect
decreas
rate
reactiv
latent
infect
second
indirect
benefit
decreas
rate
infect
patient
receiv
haart
discontinu
longtim
prophylact
antimicrobi
therapi
lead
decreas
rate
antibioticassoci
enter
infect
clostridium
difficil
well
lower
rate
drug
reaction
third
consequ
haart
resolut
ongo
infect
probabl
repopul
peripher
cell
recent
report
indic
viral
load
decreas
intestin
mucosa
cell
repopul
mucosa
haart
repopul
occur
rapidli
intestin
mucosa
blood
earlier
report
suggest
heretofor
untreat
inadequ
treatabl
enter
infect
cryptosporidium
could
improv
clinic
microbiolog
zdv
howev
natur
histori
cryptosporidiosi
variabl
recent
casecontrol
studi
show
use
antiretrovir
therapi
associ
signific
absolut
protect
infect
cryptosporidium
open
random
trial
among
patient
previous
diagnos
infect
persist
diarrhea
symptom
resolv
pathogen
undetect
stool
patient
microsporidia
enterocytozoon
bieneusi
patient
concomit
cryptosporidium
addit
pi
indinavir
nrti
similarli
among
patient
chronic
diarrhea
associ
microsporidiosi
n
cryptosporidiosi
n
n
antiparasit
therapi
fail
haart
induc
complet
resolut
symptom
weight
gain
median
week
therapi
organ
detect
patient
evalu
mark
histolog
improv
observ
biopsi
perform
howev
diarrhea
recur
patient
median
month
rang
month
patient
fail
respond
antiretrovir
therapi
increas
plasma
load
decreas
cell
number
patient
evalu
time
persist
cryptosporidium
parvum
infect
resolv
haart
associ
decreas
viral
rna
dramat
sustain
increas
cell
number
blood
intestin
mucosa
given
promis
result
specul
haart
also
improv
one
difficult
challeng
complic
infect
chronic
diarrhea
unknown
etiolog
often
refer
aid
enteropathi
awar
potenti
pathogen
increas
among
clinician
pathologist
diagnost
techniqu
becom
sophist
sensit
includ
stain
diagnost
antibodi
cultur
electron
microscopi
polymeras
chain
reaction
number
patient
complic
decreas
microsporidiosi
viral
infect
includ
cytomegaloviru
adenoviru
intestin
malign
kaposi
sarcoma
nonhodgkin
small
bowel
lymphoma
assum
increas
import
among
patient
aid
enteropathi
nevertheless
patient
diarrhea
without
identifi
pathogen
potenti
pathogen
treatabl
thu
report
haart
induc
sustain
clinic
improv
patient
chronic
diarrhea
unknown
etiolog
extrem
encourag
patient
frustrat
physician
hepat
c
viru
lead
caus
chronic
hepat
among
patient
unit
state
intraven
drug
user
patient
hemophilia
make
major
coinfect
patient
hcvinfect
hemophiliac
men
coinfect
natur
histori
patient
dual
infect
differ
adult
compar
patient
hcv
alon
concomit
infect
higher
hcv
rna
level
blood
liver
tissu
rapid
progress
liver
diseas
possibl
increas
rate
death
relat
hepat
diseas
hcv
viral
load
typic
increas
advanc
immunosuppress
thu
invers
proport
cell
number
despit
acceler
cours
hcv
replic
associ
liver
diseas
coinfect
hcv
usual
appear
promot
progress
diseas
increas
mortal
howev
increas
risk
death
new
aidsdefin
ill
well
delay
recoveri
cell
antiretrovir
therapi
recent
report
among
swiss
patient
hcv
increas
risk
primarili
associ
intraven
drug
use
unrel
progress
liver
diseas
respons
hcv
antivir
therapi
interferon
among
patient
coinfect
appear
similar
among
subject
approxim
quarter
patient
sustain
virolog
respons
month
discontinu
therapi
respond
high
cell
count
cellsl
preliminari
data
suggest
effect
therapi
ribavirin
may
greater
alon
among
seroneg
patient
although
anemia
import
complic
anoth
option
therapi
group
haart
among
patient
hepat
b
initi
potent
antiretrovir
therapi
may
lead
resolut
chronic
infect
develop
antibodi
hepat
b
surfac
antigen
sever
seri
monitor
hcv
statu
patient
haart
level
plasma
hcv
transaminas
show
transient
clinic
inappar
increas
hcv
transaminas
howev
hcv
rna
decreas
limit
detect
small
minor
observ
otherwis
healthi
patient
initi
infect
although
sever
clinic
inappar
hepat
occur
patient
upon
initi
haart
presenc
coinfect
hcv
serv
primari
determin
decis
begin
effect
antiretrovir
therapi
rel
infrequ
immun
restor
syndrom
deleteri
inflammatori
respons
even
reactiv
infect
eg
cmv
mac
follow
haart
appear
affect
hcv
infect
consist
degre
patient
diseas
effort
limit
impact
hcv
infect
includ
limit
alcohol
use
administ
hepat
vaccin
patient
seroneg
monitor
hepat
transaminas
level
consid
specif
therapi
hcv
erad
infect
limit
progress
liver
injuri
signific
hepat
patholog
despit
remark
abil
haart
measur
dramat
decreas
level
plasma
rate
opportunist
infect
antiretrovir
therapi
suffici
erad
infect
patient
moreov
undetect
rna
level
achiev
third
half
patient
haart
nonstudi
set
impair
access
care
particularli
among
black
latino
uninsur
underinsur
women
certain
risk
group
also
reduc
impact
haart
commun
addit
high
cost
inabl
patient
toler
dozen
pill
per
day
even
among
access
regular
skill
care
significantli
affect
respons
haart
gastroenterologist
may
routin
serv
primari
care
physician
patient
infect
often
consult
evalu
gastrointestin
symptom
patient
receiv
haart
consequ
awar
toxic
associ
antiretrovir
support
drug
tabl
gener
gastrointestin
symptom
nausea
vomit
abdomin
pain
diarrhea
often
occur
earli
cours
therapi
may
abat
time
gastrointestin
toxic
significantli
limit
initi
toler
proteas
inhibitor
often
requir
dose
escal
sequenti
addit
medic
nucleosid
analogu
rti
hepat
toxic
often
associ
longterm
therapi
typic
mild
although
sever
hepat
toxic
particularli
proteas
inhibitor
ritonavir
may
requir
discontinu
medic
pancreat
specif
complic
individu
drug
immunocompromis
host
treat
multipl
medic
organ
marrow
transplant
patient
rate
toxic
reaction
ascrib
drug
may
confound
concomit
administr
drug
increas
rate
advers
event
pancreat
hepat
toxic
also
may
result
simultan
administr
medic
overlap
toxic
moreov
differenti
symptom
drug
toxic
opportunist
infect
may
requir
care
evalu
time
event
presenc
comorbid
find
advers
effect
antiretrovir
therapi
may
sever
compromis
effect
patient
care
particularli
abil
consist
reduc
viral
load
poor
adher
drug
regimen
event
may
common
among
patient
advanc
diseas
cell
rate
specif
intestin
complic
agent
summar
tabl
among
patient
take
nrti
gastrointestin
symptom
includ
nausea
vomit
abdomin
pain
diarrhea
occur
quarter
patient
inhibit
cellular
dna
polymeras
includ
mitochondri
polymeras
longterm
therapi
may
result
mitochondri
toxic
associ
myopath
neuropath
hepat
pancreat
hematolog
complic
among
take
nnrti
gastrointestin
hepat
toxic
common
mild
rash
predomin
side
effect
drug
interact
nnrti
relat
primarili
effect
induc
substrat
cytochrom
system
frequent
doselimit
toxic
pi
diarrhea
nausea
abdomin
discomfort
hepat
toxic
often
associ
ritonavir
presenc
chronic
hepat
b
hepat
c
may
increas
rate
necessarili
sever
hepat
effect
infect
limit
initi
haart
recent
attent
focus
number
metabol
complic
particularli
picontain
regimen
less
often
nrti
abnorm
includ
glucos
intoler
elev
triglycerid
cholesterol
level
enigmat
disturb
complic
refer
lipodystrophi
syndrom
patient
last
syndrom
increas
abdomin
fat
loss
peripher
subcutan
fat
includ
face
arm
leg
buttock
presenc
absenc
buffalo
hump
women
therapi
may
experi
breast
enlarg
condit
may
occur
concomitantli
separ
rate
observ
fat
redistribut
pi
dual
nrti
mitochondri
dysfunct
invok
one
potenti
unifi
mechan
underli
syndrom
patient
take
picontain
combin
therapi
first
condit
may
treat
standard
medic
manag
whether
discontinu
medic
revers
potenti
disfigur
effect
lipodystrophi
syndrom
current
unclear
manag
advers
event
antiretrovir
therapi
may
complic
difficulti
identifi
specif
incit
agent
multidrug
regimen
mani
toxic
effect
antiretrovir
medic
may
wors
earli
cours
treatment
dose
depend
lower
dose
period
may
allow
therapi
continu
howev
optim
antiretrovir
activ
usual
dose
depend
particularli
pi
develop
resist
real
danger
monitor
clinic
virolog
statu
import
chang
antiretrovir
agent
may
prefer
lower
dose
evalu
overlap
toxic
differ
medic
effect
drug
metabol
may
allow
success
continu
critic
agent
regard
patient
ask
unrecord
nontradit
agent
may
take
sever
prolong
complic
requir
discontinu
individu
agent
develop
hypersensit
reaction
abacavir
gastrointestin
symptom
common
may
quit
difficult
resolv
antidiarrh
agent
loperamid
diphenoxyl
atropin
may
use
drugrel
diarrhea
may
antiemet
vomit
take
medic
eat
appropri
may
limit
nausea
histamin
receptor
blocker
antacid
although
commonli
prescrib
may
affect
absorpt
drug
usual
ineffect
major
observ
propos
drug
interact
associ
pi
relat
high
affin
thu
inhibit
sever
isoenzym
addit
medic
shown
tabl
complet
list
discuss
drug
interact
pi
avail
manufactur
articl
dolan
et
al
burger
et
al
cisaprid
potenti
lifethreaten
cardiotox
effect
presenc
proteas
inhibitor
azol
antifung
macrolid
abil
agent
inhibit
hepat
metabol
cisaprid
clinic
signific
interact
pi
rifampinrifabutin
macrolid
erythromycin
clarithromycin
azithromycin
azol
antifung
ketoconazol
fluconazol
itraconazol
highlight
tabl
chelat
effect
didanosin
antacid
iron
calcium
product
sucralf
limit
absorpt
level
quinolon
antibiot
commonli
use
empir
direct
treatment
acut
bacteri
diarrhea
summari
clinic
care
patient
improv
dramat
last
decad
greater
understand
pathogenesi
viru
rapid
clinic
diagnosi
diseas
complic
avail
potent
antimicrobi
antiretrovir
agent
resolv
prevent
opportunist
infect
advanc
bring
new
hope
well
new
challeng
provid
afford
therapi
need
manag
immunolog
clinic
complic
haart
particularli
enter
toxic
greatest
challeng
use
newli
gain
insight
pathogenesi
primari
infect
mucos
site
provid
protect
first
exposur
viru
subsequ
irrevers
declin
mucos
defens
mechan
